Question to the Department of Health and Social Care:

To ask His Majesty's Government how many yellow card reports of (1) tinnitus (Medical Dictionary for Regulatory Activities (MedDRA) code 10043882), and (2) worsening of tinnitus (MedDRA code 10048029), the Medicines and Healthcare products Regulatory Agency received in each year since 2014, and what medications those reported were linked to.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses the available data, including from the Yellow Card scheme, and seeks advice from the Commission on Human Medicines, the MHRA’s independent advisory committee, where appropriate, to inform regulatory decisions, including amending the product information.

The MHRA has received a total of 11,348 United Kingdom based reports through the Yellow Card scheme associated with reaction term tinnitus, including worsening of tinnitus, from 1 January 2014 up to and including 27 November 2025. The reports received between 2014 and 2025 were for a wide range of medicinal products which include antidepressants, hormonal medicines, vaccines, antipsychotics, antibiotics, cardiovascular medicines, drugs used to treat attention deficit hyperactivity disorder, sedatives, drugs used to treat dementia and diabetes, drugs used to treat osteoporosis, Parkinson’s disease, and pain. The following table shows a yearly breakdown of reports associated with tinnitus, from 2014 to 2025, and in total:

It is important to note that anyone can report to the MHRA’s Yellow Card scheme and the recording of these reports in the Yellow Card database does not necessarily mean that the adverse reactions have been caused by the suspect drug. Many factors must be considered in assessing causal relationships, including temporal association, the possible contribution of concomitant medication, and the underlying disease. We encourage reporters to report suspected adverse reaction reports, and the reporter does not have to be sure of a causal association between the drug and the reactions, as a suspicion will suffice.

The number of reports received cannot be used as a basis for determining the incidence of a reaction, as neither the total number of reactions occurring, nor the number of patients using the drug, is known. All fatal reports, including those reporting completed suicide, are assessed by the MHRA, and cumulative information is reviewed at regular intervals.